Posted by Michael Wonder on 13 May 2020
Gilead strikes deal to make remdesivir coronavirus treatment in 127 countries
12 May 2020 - Gilead Sciences has struck a licensing agreement with five generic drugmakers to make anti-viral drug remdesivir in 127 countries, not including the United States.
Drug makers Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences will manufacture remdesivir for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries” that face health-care obstacles amid the coronavirus pandemic, the company said.
The deal is “royalty-free” until the World Health Organization says the COVID-19 outbreak is no longer a global health crisis or “until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier,” the company said.
